News articles about Johnson & Johnson (NYSE:JNJ) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.0561399511904 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Up or Down: Johnson & Johnson, (NYSE: JNJ) (topstocksnews.com)
- 5 ways consumer products companies can help carriers improve efficiency (greenbiz.com)
- Johnson & Johnson Faces Three Talc Powder Trials In September, CVN To Webcast Live (blog.cvn.com)
- J&J hip implants: Govt sets up new panel to decide final compensation for patients (economictimes.indiatimes.com)
- Compensate those affected by faulty hip implants: Centre to Johnson & Johnson (economictimes.indiatimes.com)
Shares of JNJ opened at $135.86 on Thursday. The firm has a market cap of $361.36 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 2.05 and a beta of 0.69. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. The business had revenue of $20.83 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.83 EPS. equities research analysts forecast that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th will be given a dividend of $0.90 per share. The ex-dividend date is Monday, August 27th. This represents a $3.60 annualized dividend and a yield of 2.65%. Johnson & Johnson’s payout ratio is currently 49.32%.
A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Finally, TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $142.34.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.